Lupuzor - Orion, the final step before regulatory approval. Patient recruitment is anticipated to occur in up to 45 investigator sites, 10 in the United States and 35 in Europe. In the US the first patient dosing commenced in February 2016. In Europe, the first sites have opened in France and patient recruitment has commenced. The trial progress can be tracked on the www.ClinicalTrials.gov/lupuzor website and the key milestone for this year is for the recruitment of the 200 Lupus patients, with top-line results from the trial expected to be available in late 2017.
